Research and Science
Partnering With Leaders in Melanoma
American Association for Cancer Research (AACR) APRIL 5–10, 2024; SAN DIEGO, CA Two oral and one poster presentations of MRF-funded research
Hosted the NRAS Workshop
American Society of Clinical Oncology (ASCO) MAY 31–JUNE 4, 2024; CHICAGO, IL • H osted the MRF Breakthrough Consortium Meeting and booth in the Advocacy Pavilion to promote the MRF’s research and science grant program. • Attended several sessions related to the results of melanoma clinical trials, many of which may lead to practice changing advancements related to: neoadjuvant vs. adjuvant therapy; immunotherapy and targeted therapy. To learn more about the ASCO presentations view: Promising Research
OCTOBER 2024 Workshop co-chairs:
MRFBC co-chairs (from L to R) —
Dr. Adil Daud UCSF Health
Dr. Martin McMahon Huntsman Cancer Institute
Dr. Keiran Smalley Moffitt Cancer Center
Richard D. Carvajal, MD, Northwell Health; Kyleigh LiPira, MRF CEO; Tara C. Mitchell, MD, Penn Medicine; and Ryan J. Sullivan, MD, Dana-Farber/ Harvard Cancer Center
The MRF convened melanoma investigators and industry representatives for a one-day workshop entitled, “Targeting RAS Signaling for Future Melanoma Therapy.” The mission of the workshop was to translate direct pharmacologic signaling of RAS from the bench to the bedside, elucidate mechanisms of response resistance and identify logical combination therapies. For melanoma patients with NRAS-driven melanoma, immunotherapy remains the front-line treatment option. For the many patients who will either not respond to or ultimately progress on immunotherapy, current options for second-line therapy are limited and not particularly effective. The advent and testing of new NRAS oncoprotein inhibitors in late-stage preclinical testing offers effective
Updates for Melanoma Patients Presented at ASCO – Melanoma Research Foundation
NRAS-targeted second-line treatments as an exciting prospect. Read Dr. McMahon’s workshop summary for more information: Targeting NRAS Oncoproteins for the Treatment of Melanoma — Melanoma Research Foundation
Society for Immunotherapy of Cancer (SITC) NOVEMBER 6–9; HOUSTON, TX One oral and four poster presentations of MRF-funded research
8 • Stewardship Report
Made with FlippingBook Ebook Creator